We performed a retrospective study to evaluate, under routine circumstances, the tolerance and immunovirological changes associated with antiretroviral regimens that contain nevirapine in 137 patients (88% were antiretroviral experienced). During a mean follow-up of 11 months, 33% of patients reported side effects attributed to nevirapine, and 21% discontinued treatment because of poor tolerance. Administration of antihistamines or corticosteroids at the initiation of treatment was not protective against adverse events (relative risk, 0.82; 95% confidence interval, 0.49-1.38). The proportion of patients with hepatitis C virus (HCV) and/ or hepatitis B virus (HBV) coinfection who had alanine aminotransferase levels of 1100 IU/L increased from 19.4% at baseline to 42.9% at month 12 of follow-up ( ). We noticed a significant increase of the P p .02 proportion of patients with total cholesterol levels of 15.5 mM ( ). We have shown that there is a high P p .02 level of discontinuation of nevirapine therapy in clinical practice and that side effects were not prevented by administration of antihistamines or corticosteroids. Coinfection with HCV or HBV increased the risk of hepatotoxicity, which lead to the cautious use of nevirapine for such patients.
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In 1997, nevirapine became the first nonnucleoside reverse-transcriptase inhibitor (NNRTI) available for the treatment of HIV-1 infection. Its efficacy was established in association with the use of nucleoside reversetranscriptase inhibitors (NRTIs) for antiretroviral-naive subjects and for pretreated patients who had switched to nevirapine from protease inhibitors (PIs) for treatment of HIV-1 infection [1] [2] [3] [4] [5] . By the time nevirapine was introduced for routine case management, its most common adverse events had already been well documented in controlled clinical trials. Because nevirapine induces its own metabolism by the liver, a regimen involving administration of 200 mg of nevirapine per day for 2 weeks has been recommended before the full daily 400-mg dose is administered. This strategy is also believed to decrease the risk of early toxicity. In the main trials of nevirapine-containing regimens, the most common side effect (occurring in 9%-32% of the patients) was the development of rash, usually within the first 4-6 weeks of therapy; the drug discontinuation rate was 6%-7%, and the incidence of Stevens-Johnson syndrome was ∼1% [1] [2] [3] [4] . The benefit of preventive treatment using antihistamines or corticosteroids is unclear [6] [7] [8] . In the same studies, hepatotoxicity was noted in 2%-5% of patients who received nevirapine, but the rate was not significantly different than the rate for patients who did not receive nevirapine [1] [2] [3] [4] . We performed a retrospective study within the French Aquitaine Cohort to describe the clinical and biological tolerance of nevirapine-containing antiretroviral regimens, as assessed under routine circumstances. 
METHODS
Study design and population. We performed this study at a clinical center participating in the French Aquitaine Cohort, which is described elsewhere [9] . In brief, this cohort comprises patients enrolled through a hospital-based surveillance system of HIV-1 infection in southwestern France. We prospectively included all HIV-1-positive inpatients and outpatients at the participating clinic wards who had completed у1 follow-up visit after enrollment in the study or for whom there was a documented date of death after the initial report; who were 113 years of age; and who provided written informed consent. Follow-up is based on current French guidelines. At each hospital visit, physicians recorded epidemiological, clinical, biological, and therapeutic data on a standardized form. We enrolled NNRTI-naive patients who were being observed at the Hô pital Saint-André (Bordeaux, France) and who had received nevirapine at least once during the period of September 1997 through May 1999. For these patients, a complementary data form was completed using information from the medical records to obtain more information about events related to clinical intolerance. Evaluation criteria. Clinical tolerance (cutaneous, digestive, constitutional, and other events) and biological tolerance were assessed every 3 months from September 1997 through December 1999. Biological tolerance was determined according to changes in the serum levels of alanine aminotransferase (ALT), triglyceride, and cholesterol. For the ALT level, we chose an a priori cutoff of 100 IU/L, because this corresponds to 2 times the upper limit of the normal range for our laboratory. The management of nevirapine-associated side effects was the responsibility of each practitioner, in accordance with the current French guidelines [10] . We also noted the occurrence of AIDS-related events, death, and changes in the plasma virus load (as determined by use of bDNA Chiron 2. Changes in the proportion of patients who presented with biological disorders were assessed using a logistic model with a random intercept to take into account the repeated measures in each subject. This change was considered to be linear with time. The model was fitted using the NLMIXED procedure on SAS software (SAS Institute).
RESULTS
Description of the study sample. One hundred thirty-seven patients were included in the study. Of these patients, 99 (72%) were male, 58 (42%) were homosexual, 44 (32%) were injection drug users, and 24 (17%) were heterosexual. The median patient age at the time of initiation of nevirapine therapy was 36 years (interquartile range [IQR], 32-43 years). HIV-1/HBV and HIV-1/HCV coinfections were serologically diagnosed in 16% and 25% of subjects, respectively, and 7% of the subjects were infected with HIV-1, HBV, and HCV. In 25% of the subjects, HIV-1 infection had progressed to AIDS.
At the initiation of nevirapine therapy, 121 patients (88%) were antiretroviral experienced (62% had a history of receiving a 2-drug regimen). Of these patients, 37 (31%) switched only 1 drug to nevirapine; 27 patients made this switch to simplify therapy or because of PI-related side effects in the context of virological success (HIV-1 RNA level, !500 copies/mL), and 10 patients made the switch in the context of treatment failure. Twenty-one patients (17%) had nevirapine alone added to the previous combination therapy, and 63 patients (52%) had у1 new drug added to treatment with nevirapine. Nevirapine was prescribed in combination with 2 NRTIs for 98 (72%) of 137 patients, with 1 NRTI and 1 PI for 28 patients (20%), and with other combinations (generally 2 PIs) for 11 patients (8%). Stavudine and lamivudine were the NRTIs most frequently used in association with nevirapine (table 1). In 85% of patients, nevirapine was administered in a lead-in regimen of 200 mg q.d. for 2 weeks, followed thereafter by twice-daily administration of 200 mg. For prevention of nevirapine-associated rash, antihistamines were prescribed for 25 patients (18%), corticosteroids were prescribed for 19 patients (14%), and both were prescribed for 3 patients (2%).
At baseline, the median CD4 ϩ cell count was 334 cells/mL (IQR, 207-449 cells/mL) and the HIV-1 RNA level was 10,428 copies/mL (4.02 log 10 copies; IQR, 3700-31,934 copies/mL). Ninety-four (78%) of the 121 antiretroviral-experienced patients had HIV-1 RNA levels of у500 copies/mL. Other characteristics at baseline for the overall sample were as follows: Clinical tolerance. During a mean follow-up of 11 months (127 person-years), side effects attributed to nevirapine were reported by 46 subjects (33%), with 67 cases of drug intolerance reported (table 2) . The median time from the initiation of treatment to the occurrence of adverse events was 68 days (IQR, 27-196 days). Adverse events mostly consisted of mucocutaneous events, such as maculopapular rash (27 cases), pruritus (5 cases), urticaria (5 cases), Stevens-Johnson syndrome (1 case), and Quincke edema (1 case). There were 39 cases of cutaneous intolerance among 31 patients (23% of our cohort); 3 manifestations of intolerance (urticaria, Stevens-Johnson syndrome, and Quincke edema) were retrospectively considered to have been grade 3 or 4 intolerance. Fifteen patients (11%) had only extracutaneous manifestations of intolerance, constitutional symptoms, digestive events, and musculoskeletal events. Twenty-nine subjects (21%) had to definitively discontinue nevirapine therapy because of poor tolerance (figure 1), after which there was resolution of the iatrogenic adverse events.
Follow-up of the cohort was independent of the occurrence of drug intolerance events. No epidemiological, clinical, biological, or therapeutic factors were found to be predictive of adverse events. In particular, PI combination treatment was not associated with poor clinical tolerance for the regimen containing nevirapine (relative risk [RR], 1.23; 95% CI, 0.75-2.01). Administration of antihistamines or corticosteroids at the in- itiation of nevirapine treatment was not protective against adverse events (RR, 0.84; 95% CI, 0.50-1.41). Biological tolerance. The proportion of HCV-and HBVuninfected patients with ALT levels of 1100 IU/L increased slightly, from 2.5% at baseline to 9.0% at month 12, which was statistically significant (OR for each 3 months, 1.23; ; P p .32 table 3). The proportion of HCV-and/or HBV-coinfected patients with ALT levels of 1100 IU/L increased from 19.4% at baseline to 42.9% at month 12 (OR for each 3 months, 1.73; ). The difference between patients with and patients with-P p .02 out HBV and/or HCV coinfection remained when analysis excluded patients who were receiving treatment that included PIs: the proportion of patients with ALT levels of 1100 IU/L increased from 1.8% at baseline to 5.9% at month 12 (OR for each 3 months, 1.50; ) in patients without HBV and/or HCV P p .24 coinfection, and it increased from 14.8% to 45.5% (OR for each 3 months, 2.1; ) in patients with coinfection. P p .07 There was a significant increase over time in the proportion of patients with a total cholesterol level of 15.5 mM, from 22.6% of patients at baseline to 38.2% of patients at month 12 (OR for each 3 months, 1.48;
; table 4). This increase re-P p .002 mained statistically significant (OR for each 3 months, 1.54; ) when we excluded patients who were taking a PI in P p .04 combination with nevirapine: the percentage of patients who had a total cholesterol level of 15.5 mM increased from 17.6% at baseline to 30.8% at month 9 and to 20.6% at month 12 (the findings for 29 patients were available at month 12). No significant modification in triglyceride levels was observed (OR for each 3 months, 1.11;
). Data regarding high-density P p .40 lipoprotein and low-density lipoprotein cholesterol levels were not available for analysis.
Immunovirological changes. Data were available for the 94 pretreated subjects with HIV-1 RNA levels of у500 copies/mL at the initiation of the nevirapine-containing regimen. Twentyfive percent of these subjects' infections had progressed to AIDS. The median CD4 ϩ cell count was 322 cells/mL, the median HIV-1 RNA level was 13,900 copies/mL (4.14 log 10 copies), and, after a median duration of follow-up of 343 days, 10 deaths and 7 new opportunistic infections were reported. By month 6 of nevirapine treatment, 35% of these patients had discontinued therapy; by month 9, 43% had discontinued it; by month 12, 51% had discontinued it. The median HIV-1 RNA levels and CD4 ϩ cell counts did not improve significantly during follow-up (data not shown). Thus, the HIV-1 RNA level was у500 copies/mL in 85% of subjects at baseline, in 57% at month 3, in 63% at month 6, and in 70% at month 12; the CD4 ϩ cell count was !200 cells/mL in 26% of subjects at baseline, in 22% at month 3, in 21% at month 6, and in 25% at month 12.
DISCUSSION
In our cohort of patients, who were observed under routine circumstances, adverse events associated with nevirapine use were more common than has been reported in most previously published controlled clinical trials. The events were mainly cutaneous, as reported by others, but we also noticed constitutional symptoms, digestive events, and musculoskeletal events, which have been poorly described in the literature [11] . We cannot exclude iatrogenic side effects associated with use of NRTI or PI combinations, but the following should be noted:
(1) the median time from the initiation of a regimen containing nevirapine to the occurrence of adverse events was relatively short (68 days) and, thus, was less indicative of the cumulative toxicity of NRTIs; (2) nevirapine was the only new drug introduced in the combination therapy for one-half of the patients; (3) for all adverse events that led to the discontinuation of nevirapine (∼20% of discontinuations), iatrogenic adverse events resolved after the discontinuation of nevirapine alone; and (4) as far as metabolic disturbances are concerned, similar results were found regardless of whether analyses were restricted to patients receiving a PI. No deaths related to nevirapine use were observed. Even if the incidence of cutaneous intolerance seems to be much higher than that reported in most clinical trials, side effects of grade 3 or 4 were noted in only 3 cases. Most discontinuations of therapy were for patients who had у2 side effects of grade 1 or 2, as recommended. Our study reflects the difficulties encountered by practitioners in deciding whether to continue administration of nevirapine when only a single grade 1 or 2 side effect is noted. One important finding is that we did not identify any benefit for the prevention of subsequent clinical adverse events associated with the addition of steroids or antihistamines at the initiation of nevirapine therapy. These results are not in agreement with the findings of Bareiro et al. [7] , who, in a prospective study, showed that the incidence of rash that complicates the first few weeks of treatment with nevirapine can be diminished by adding corticosteroids for the first 2 weeks or by administering a slowly escalating dose of nevirapine (100 mg q.d. for the first week, increasing by 100 mg per week to a dosage of 400 mg q.d.) [7] .
Other studies have shown results that are in agreement with our conclusions. Rey et al. [6] showed that prednisolone had no beneficial effect for the prevention of nevirapine-induced rashes, and Antinori et al. [8] identified female sex and the use of antiallergic agents (glucocorticoids and antihistamines) as risk factors for developing cutaneous rash associated with nevirapine therapy [8] . Recently, the only prospective, randomized study of this topic showed that short-term therapy with prednisone does not prevent nevirapine-associated rash and might even increase its incidence and severity [12] . The differences in the definitions of adverse events, the compositions of the study populations, and the use of combination therapy and associated treatments might have contributed to the apparent discrepancies between the study findings. Altogether, the arguments made to date are against the prescription of corticosteroids or antihistamines to prevent rash at the initiation of a nevirapine-containing treatment regimen.
With regard to hepatic intolerance, our results at 12 months of follow-up in the overall cohort are similar to those of Martinez et al. [13] , even though the definitions of hepatotoxicity were slightly different (a у3-fold increase in the ALT level was used by Martinez et al. [13] and a level of up to 100 IU/L was used for our study). Hepatotoxicity was mainly noted in patients with HCV and/or HBV coinfection who were receiving regimens that contained nevirapine (without a PI), with the incidence of hepatotoxicity increasing steadily over time, to 45% at month 12 of follow-up. Martinez et al. [13] did not study the subgroup of HBC-and/or HCV-coinfected patients like we did, but, on multivariate analysis, they found that patients who were seropositive for HCV had a 2.5-fold increased risk of developing hepatotoxicity, and that those with elevated ALT levels at baseline had a 1.5-fold increased risk of developing hepatotoxicity [13] . We noticed that hepatotoxicity was not significantly increased at month 12 in patients without HCV or HBV coinfection. We did not observe any cases of severe biological hepatotoxicity (i.e., an ALT level of 1200 IU/L) or clinical hepatitis during the first year of follow-up, but some cases have been reported in the literature, as have cases of liver failure [13] [14] [15] [16] . Coinfection with HCV and/or HBV and receipt of therapy that contains a PI contribute to the increased risk of hepatotoxicity, and we think that nevirapine therapy should be carefully considered for such patients, for whom prescribers should prefer another NNRTI. De Requena et al. [17] suggested that monitoring of nevirapine levels in plasma may be warranted, especially for patients with chronic HCV infection. The incidence of hepatic intolerance was higher than expected, compared with that noted in clinical trials, in which, for the most part, inclusion criteria did not allow for the recruitment of HBV-or HCV-coinfected patients. One of the explanations for the higher risk of hepatotoxicity associated with nevirapine in HBV-and/or HCV-coinfected patients could be the increased area under the curve for nevirapine concentrations (up to 40%) in patients with hepatic dysfunction [18] . In fact, there are certainly several possible mechanisms of nevirapine toxicity. Hypersensitivity could provide an explanation for the early cutaneous side effects and cases of fulminant hepatitis that are reported in the literature; however, we demonstrated that the risk of hepatotoxicity increased steadily over time, which indicates a direct toxicity of nevirapine on hepatocytes or a cytolysis associated with immune restoration, as described with PIs [19] .
One important argument in favor of the use of nevirapine is the moderate impact of this drug on metabolic parameters, compared with PIs or other NNRTIs (such as efavirenz), and the fact that these metabolic abnormalities could reverse after switching from PI to nevirapine [5, 20] . Our results are slightly discordant with the results of previous publications with regard to this. In our cohort, in which 28% of the patients were receiving combination therapy that included a PI, we showed that the proportion of patients with total cholesterol levels of 15.5 mM increased significantly during follow-up. This remained true even when we excluded patients who received PIs.
Our study has some limitations. First, it was retrospective in nature and a limited number of patients were studied. Second, fasting conditions may have not been verified for some plasma measurements. Third, high-density lipoprotein and low-density lipoprotein cholesterol values were not available. Recent studies have shown that the use of nevirapine could lead to an increase in both high-density lipoprotein and low-density lipoprotein cholesterol levels; however, nevirapine is associated with a decrease in the atherogenic ratio of total cholesterol to highdensity lipoprotein cholesterol when compared with other treatment regimens that include a PI or efavirenz [20] [21] [22] . If confirmed in other studies, these results could influence the initial choice of antiretroviral combinations, especially for patients with a high risk of developing atherogenic disease.
Although we described immunovirological changes in an intent-to-treat approach, the context and the population of our study do not allow us to perform a full evaluation of the field efficacy of nevirapine. In our study, it appears that immunovirological response was limited for patients who had the mostadvanced HIV-1 disease or who were antiretroviral experienced; all the more, no drug other than nevirapine was added to therapy for one-half of the patients. However, these observations do not preclude better performance of regimen containing nevirapine in antiretroviral-naive patients or in patients for whom therapy is switched from PIs to nevirapine, on the basis of results of the genotypic assays in the context of virological failure.
In conclusion, in this cohort of patients who were treated with nevirapine-containing regimens in routine clinical practice, we have shown that there was a high rate of treatment discontinuation due to clinical side effects that were not prevented by use of antihistamines or corticosteroids. Patients with HCV and/or HBV coinfection often presented with hepatotoxicity, which lead us to be cautious in the use of nevirapine for such patients. Finally, the impact of nevirapine on metabolic disorders is still debatable and should continue to be assessed in antiretroviral-experienced and -naive patients who initiate a regimen that contains nevirapine.
